Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.

Esther E Freeman ; Richard G White ORCID logo ; Roel Bakker ; Kate K Orroth ; Helen A Weiss ORCID logo ; Anne Buvé ; Richard J Hayes ORCID logo ; Judith R Glynn ORCID logo ; (2009) Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine, 27 (6). pp. 940-946. ISSN 0264-410X DOI: 10.1016/j.vaccine.2008.11.074
Copy

Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. Intensified efforts are needed to develop an effective HSV2 vaccine.


picture_as_pdf
main.pdf
subject
Published Version
Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads